Antagonist of the miRNA-106b-5p to treat or prevent the cardiotoxicity that is developed in oncologic patients after receiving anthracycline-based chemotherapy

  1. Inventors:
  2. Domingo Andres Pascual Figal
  3. Antonio Manuel Lax Perez
  4. Maria del Carmen Asensio Lopez
  1. Universidad de Murcia
    info
    Universidad de Murcia

    Murcia, España

    Geographic location of the organization Universidad de Murcia
WO EP US
Publicación principal:

WO2023073118A1 (04-05-2023)

Otras Publicaciones:

EP4174176A1 (03-05-2023)

EP4423270A1 (04-09-2024)

WO2023073118A1 (04-05-2023)

US20240417727A1 (19-12-2024)

Abstract

It is herein demonstrated that an increase in Dox-induced miRNA-106b-5p (miR-106b) is able to down-regulate PR55α subunit, which leds to a decrease both in PP2A activity as well as an accumulation of the phosphorylated HDAC4 protein in cytosol. Anti-miRNA-106b-5p (miR- 106b) therapy is thus able to prevent Dox-induced PR55α degradation, facilitate the HDAC4 dephosphorylation by PP2A, and increase HDAC4-YY1 interaction, resulting in a decreased in sST2 expression and release by the LV myocardium. Further, and for first time, it has identified the role that sST2 isoform plays in Dox-induced CTX.

lock_openWO2023073118A1